NCT05780216View on ClinicalTrials.gov

Mindfulness and Psychedelics

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

August 5, 2023

Study Completion Date

September 15, 2023

Conditions
Healthy Participants
Interventions
DRUG

DMT + harmine

The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.

DRUG

Placebo

The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.

Trial Locations (1)

8032

Psychiatric University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

University Medical Center Freiburg

OTHER

lead

Milan Scheidegger

OTHER